Skip to main content

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
Moreira, DM; Howard, LE; Sourbeer, KN; Amarasekara, HS; Chow, LC; Cockrell, DC; Hanyok, BT; Pratson, CL; Aronson, WJ; Kane, CJ; Terris, MK ...
Published in: Prostate cancer and prostatic diseases
December 2015

To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.Retrospective analysis of 531 bone scans of 312 clinically CRPC patients with no known metastases at baseline treated with a variety of primary treatment types in the SEARCH database. The association of patients' demographics, pathological features, PSA levels and kinetics with risk of a positive scan was tested using generalized estimating equations.A total of 149 (28%) scans were positive. Positive scans were associated with younger age (odds ratio (OR)=0.98; P=0.014), higher Gleason scores (relative to Gleason 2-6, Gleason 3+4: OR=2.03, P=0.035; Gleason 4+3 and 8-10: OR=1.76, P=0.059), higher prescan PSA (OR=2.11; P<0.001), shorter prescan PSA doubling time (PSADT; OR=0.53; P<0.001), higher PSA velocity (OR=1.74; P<0.001) and more remote scan year (OR=0.92; P=0.004). Scan positivity was 6, 14, 29 and 57% for men with PSA<5, 5-14.9, 15-49.9 and ⩾ 50 ng ml(-1), respectively (P-trend <0.001). Men with PSADT ⩾ 15, 9-14.9, 3-8.9 and <3 months had a scan positivity of 11, 22, 34 and 47%, correspondingly (P-trend <0.001). Tables were constructed using PSA and PSADT to predict the likelihood of a positive bone scan.PSA levels and kinetics were associated with positive bone scans. We developed tables to predict the risk of positive bone scans by PSA and PSADT. Combining PSA levels and kinetics may help select patients with CRPC for bone scans.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate cancer and prostatic diseases

DOI

EISSN

1476-5608

ISSN

1365-7852

Publication Date

December 2015

Volume

18

Issue

4

Start / End Page

333 / 337

Related Subject Headings

  • Urology & Nephrology
  • Sensitivity and Specificity
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Prognosis
  • Odds Ratio
  • Neoplasm Grading
  • Male
  • Humans
  • Bone and Bones
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., … Freedland, S. J. (2015). Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 18(4), 333–337. https://doi.org/10.1038/pcan.2015.25
Moreira, D. M., L. E. Howard, K. N. Sourbeer, H. S. Amarasekara, L. C. Chow, D. C. Cockrell, B. T. Hanyok, et al. “Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.Prostate Cancer and Prostatic Diseases 18, no. 4 (December 2015): 333–37. https://doi.org/10.1038/pcan.2015.25.
Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2015 Dec;18(4):333–7.
Moreira, D. M., et al. “Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.Prostate Cancer and Prostatic Diseases, vol. 18, no. 4, Dec. 2015, pp. 333–37. Epmc, doi:10.1038/pcan.2015.25.
Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2015 Dec;18(4):333–337.

Published In

Prostate cancer and prostatic diseases

DOI

EISSN

1476-5608

ISSN

1365-7852

Publication Date

December 2015

Volume

18

Issue

4

Start / End Page

333 / 337

Related Subject Headings

  • Urology & Nephrology
  • Sensitivity and Specificity
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Prognosis
  • Odds Ratio
  • Neoplasm Grading
  • Male
  • Humans
  • Bone and Bones